Pluri (NASDAQ: PLUR) and Remedy Cell have expanded their manufacturing collaboration, achieving an important milestone as clinical-grade production of Remedy Cell’s lead therapeutic candidate has…
December 22, 2025
December 22, 2025
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Hepatitis C Trial
Atea Pharmaceuticals (NASDAQ: AVIR) has completed patient enrollment in its C-BEYOND Phase 3 clinical trial, a pivotal study evaluating an oral, fixed-dose combination of bemnifosbuvir…
December 18, 2025
BioNTech Completes CureVac Acquisition, Expanding Its mRNA Platform
BioNTech SE ( NASDAQ: BNTX) has completed its acquisition of CureVac N.V., closing its public exchange offer and moving toward full integration of the two…
December 18, 2025
Pyxis Oncology Reports Encouraging Early Phase 1 Results for MICVO in Advanced Head and Neck Cancer
Pyxis Oncology, Inc. (NASDAQ: PYXS) has reported positive preliminary data from ongoing Phase 1 studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent or metastatic…
December 16, 2025
Rezolute Reports Phase 2b Proof of Concept for Rezpegaldesleukin in Severe Alopecia Areata
Rezolute, Inc. (Nasdaq: NKTR) announced positive results from its Phase 2b clinical study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, establishing…
December 11, 2025
AC Immune Posts Strong Phase 2 Interim Data for ACI-7104.056 in Parkinson’s Disease
AC Immune (NASDAQ: ACIU) announced encouraging interim data from its Phase 2 VacSYn study evaluating ACI-7104.056, an active immunotherapy designed to generate antibodies against misfolded…
December 11, 2025
Okyo Pharma Reports Encouraging Corneal Nerve Improvements in Phase 2 Study for Neuropathic Corneal Pain
Okyo Pharma (NASDAQ: OKYO) released new Phase 2 data showing that its lead candidate OK-101 produced favorable corneal nerve changes in patients with neuropathic corneal…
November 03, 2025
Phio Pharmaceuticals Reports Positive Pathology Results for PH-762 in Skin Cancer Trial
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced encouraging pathology results from the fourth cohort of its ongoing Phase 1b clinical trial evaluating PH-762, the company’s lead…
AI-driven sustained-delivery therapy now advancing in two major retinal disease markets; new preclinical data highlights dual VEGF and IL-6 inhibition mechanism. EyePoint Pharmaceuticals, Inc. (NASDAQ:…
July 15, 2025
Kairos Pharma Surges 165% on Positive Phase 2 Safety Data for Prostate Cancer Therapy ENV-105
Kairos Pharma Ltd. (NYSE: KAPA) jumped 165% after reporting encouraging interim safety data from its Phase 2 trial evaluating ENV-105 in combination with apalutamide (Erleada)…
February 26, 2025
Shares of Madrigal Pharmaceuticals Surge as Fresh Biennial Data Highlights Possible Advantages of Rezdiffra in Treating Compensated Fatty Liver Cirrhosis
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) revealed the two-year outcomes from the Phase 3 MAESTRO-NAFLD-1 analysis of Rezdiffra (resmetirom) in patients with compensated MASH cirrhosis on Wednesday….
August 03, 2023
Lexaria to Examine Potential Role of DehydraTECH-CBD in Diabetes Control and Weight Loss
Lexaria Bioscience (Nasdaq:LEXX) will initiate a human clinical study to investigate the potential role of its proprietary DehydraTECH-CBD in diabetes control and weight loss. Lexaria…